Severe Mucha-Habermann-Like Ulceronecrotic Skin Disease in T-Cell Acute Lymphoblastic Leukemia Responsive to Basiliximab and Stem Cell Transplant.
Lauren A V OrensteinCarrie C CoughlinAndrea T FlynnVinodh PillaiMarkus D BoosGerald B WertheimJames R TreatDavid T TeacheyPublished in: Pediatric dermatology (2018)
A 5-year-old girl with T-cell acute lymphoblastic leukemia (T-ALL) developed a progressive eruption of crusted papules and ulcerative plaques involving 80% of her body surface area with histopathology consistent with febrile ulceronecrotic Mucha-Habermann disease (FUMHD), although multiple specimens also contained clonal leukemic cells. Her skin disease was refractory to many classic treatments for FUMHD, including methotrexate, and became so severe that concern about superinfection prevented intensification of chemotherapy for her malignancy. The addition of basiliximab promoted gradual improvement of the skin, allowing for chemotherapy intensification and subsequent bone marrow transplantation, after which the eruption resolved completely. This report describes a severe case of FUMHD-like eruption associated with clonal leukemic cells that improved with basiliximab, suggesting anti-CD25 therapy as a novel treatment for ulceronecrotic skin disease in the setting of high interleukin-2 levels.
Keyphrases
- acute lymphoblastic leukemia
- bone marrow
- stem cells
- induced apoptosis
- soft tissue
- acute myeloid leukemia
- wound healing
- early onset
- multiple sclerosis
- squamous cell carcinoma
- mesenchymal stem cells
- allogeneic hematopoietic stem cell transplantation
- endoplasmic reticulum stress
- high dose
- drug induced
- cell proliferation
- locally advanced
- ultrasound guided